Oxford vaccine



FootballFan said:
I think its pretty clear what they did. Its the Financial Times reporting it man, not the Sun what won it.
Oh one more thing in the artlcle, shares in AstraZeneca are down 6% whereas Pfizer ,BioNTech , Moderna all up siginificanttly
Click to expand...
Shares in Astrozeneca are down because they said they won’t be profiting from the vaccine as they’re giving it away at cost price.
 
West_Winger said:
Shares in Astrozeneca are down because they said they won’t be profiting from the vaccine as they’re giving it away at cost price.
Click to expand...
you may as well talk to a f***ing turnip mate. Much more sense to be had. Astrazeneca down a whole 16p (0.20%)...been falling since beginning of the month

Who knew the stock market was impingent on how efficacious a drug is compared to how much dollar it makes for the company :)
 
Last edited:
FootballFan said:
Not what the FT were saying, they are pretty clear that they have misrepresented the data.
Click to expand...
No that’s literally what has happened.

“AstraZeneca, which is Britain’s biggest pharmaceutical firm, also reiterated that it would not profit from the vaccine during the current pandemic – until at least July – by pricing “at cost”, about $3 (£2.25) to $5 a dose. This is far below Pfizer’s $19.50 and Moderna’s $25 to $37 a dose.”

“The shares slipped further after an analyst at the US investment bank SVB Leerink, Geoffrey Porges, cast doubt over whether the vaccine would be licensed in the US. Porges argued that the design of the studies did not meet the norms of the Food and Drug Administration for the representation of minorities, severe cases, previously infected individuals and the elderly.
pavarotti1980 said:
you may as well talk to a f***ing turnip mate. Much more sense to be had.

Who knew the stock market was impingent on how efficacious a drug is compared to how much dollar it makes for the company :)
Click to expand...
If only they knew that to run a 3-phase trial all you had to do was announce some results and let the stock market decide whether your drug works or not they’d have saved a fortune.
 
West_Winger said:
No that’s literally what has happened.

“AstraZeneca, which is Britain’s biggest pharmaceutical firm, also reiterated that it would not profit from the vaccine during the current pandemic – until at least July – by pricing “at cost”, about $3 (£2.25) to $5 a dose. This is far below Pfizer’s $19.50 and Moderna’s $25 to $37 a dose.”

“The shares slipped further after an analyst at the US investment bank SVB Leerink, Geoffrey Porges, cast doubt over whether the vaccine would be licensed in the US. Porges argued that the design of the studies did not meet the norms of the Food and Drug Administration for the representation of minorities, severe cases, previously infected individuals and the elderly.

If only they knew that to run a 3-phase trial all you had to do was announce some results and let the stock market decide whether your drug works or not they’d have saved a fortune.
Click to expand...
Why go to phase III, just stick and at phase I and save even more. Oh look its a drug, get Doris to open the safe now for the cash to start rolling in :)

As I pointed out to said turnip before Novovax shares are up again today and they havent even released preliminary vaccine data yet....how does that work.
 
Last edited:
West_Winger said:
No that’s literally what has happened.

“AstraZeneca, which is Britain’s biggest pharmaceutical firm, also reiterated that it would not profit from the vaccine during the current pandemic – until at least July – by pricing “at cost”, about $3 (£2.25) to $5 a dose. This is far below Pfizer’s $19.50 and Moderna’s $25 to $37 a dose.”

“The shares slipped further after an analyst at the US investment bank SVB Leerink, Geoffrey Porges, cast doubt over whether the vaccine would be licensed in the US. Porges argued that the design of the studies did not meet the norms of the Food and Drug Administration for the representation of minorities, severe cases, previously infected individuals and the elderly.

If only they knew that to run a 3-phase trial all you had to do was announce some results and let the stock market decide whether your drug works or not they’d have saved a fortune.
Click to expand...

According to the FT the main cause of share price drop was misrepresenting the data.

If they price "at cost" or not the big story here is the efficacy, been several murmurings this story will run
 
FootballFan said:
According to the FT the main cause of share price drop was misrepresenting the data.

If they price "at cost" or not the big story here is the efficacy, been several murmurings this story will run
Click to expand...
No, you’ve read one article and ignored everything else. The efficacy has been proven. Your nonsense has not. The fact you appear to know so little about how the stock market works as well as how drug trials work should preclude you from commenting. I doubt it will.
 
West_Winger said:
No, you’ve read one article and ignored everything else. The efficacy has been proven. Your nonsense has not. The fact you appear to know so little about how the stock market works as well as how drug trials work should preclude you from commenting. I doubt it will.
Click to expand...

Its all over the broadcasting news man now also. Big decision for the regulators coming up
 
West_Winger said:
No, you’ve read one article and ignored everything else. The efficacy has been proven. Your nonsense has not. The fact you appear to know so little about how the stock market works as well as how drug trials work should preclude you from commenting. I doubt it will.
Click to expand...
With the greatest respect, as of this moment it hasn't and has a way to go. In fact, the efficacy of no vaccine has yet been proven.
West_Winger said:
Shares in Astrozeneca are down because they said they won’t be profiting from the vaccine as they’re giving it away at cost price.
Click to expand...
Wasn't this announced to the markets in June?
 
FootballFan said:
They kind of were telling porkies lets be fair.
Click to expand...

No they were not. They just didn't announce it in a press release.

In an interview Wednesday, Menelas Pangalos, the AstraZeneca executive in charge of much of the company’s research and development, defended the company’s handling of the testing and its public disclosures.

He said the error in the dosage was made by a contractor, and that, once it was discovered, regulators were immediately notified and signed off on the plan to continue testing the vaccine in different doses.
Click to expand...

Surely you have noticed that all the criticism is coming from Investment bankiers and they are all American. Their main criticism is ''transparency''. Response from AstraZeneca is:

Asked why AstraZeneca shared some information with Wall Street analysts and some other officials and experts but not with the public, he responded, “I think the best way of reflecting the results is in a peer-reviewed scientific journal, not in a newspaper.”
Click to expand...

John LaMattina,
Click to expand...
a former president of Pfizer’s global research and development unit, said in a tweet it was “hard to believe” US regulators would issue an emergency-use authorisation for a “vaccine whose optimal dose has only been given to 2,300 people”.
Click to expand...

This is article from New York Times (via Irish Times)

www.irishtimes.com

Admission of mistake in Oxford vaccine dose raises doubts over reliability

Odds of regulators quickly authorising emergency use of inoculation are declining
www.irishtimes.com www.irishtimes.com

All the comment has been from investment bankers who say its unlikely that the drug will be approved for use in the US by the DFA. These comments are based on them not knowing what has been disclosed to the DFA. They also fail to mention that it could be approved on 50% efficacy which it has more than reached (averaging 60-70%). The US has options on 300 million doses of the Oxford Vaccine if its approved. Its not hard to figure out why investment bankers might not want it to be approved when they are so invested in the other 2 US vaccines where there is a lot more profit to be made.
 
Last edited:
FootballFan said:
Its quite simple - they took a small dataset taken erroneously with an age group all under 55 years old, not sure what is so hard to understand.

The regulators wont pass that, breaking news they are going to go for another worldwide trial.
Click to expand...

Who said the regulators won't pass it?
 

Back
Top